Participants will be compared against two other options. One option is Trimbow, which contains the same three active ingredients. The other comparison involves using beclometasone dipropionate alone. Some individuals may also receive a placebo. The study uses a cross-over design, meaning that participants will receive different treatments at different times during the course of the study to see how each one affects their breathing.

One of the main ways the study looks at how well the medicine works is by measuring the forced expiratory volume in 1 second, which is a test that calculates how much air a person can exhale quickly to check lung function. The study tracks these changes over a period of time to see how the different inhaled medications affect breathing capacity and overall control of the condition.

The main purpose of this study is to determine if Verekitug can reduce the number of COPD flare-ups (also called exacerbations) that patients experience. During these flare-ups, COPD symptoms become worse than usual, often requiring additional medical treatment. The study will involve patients who have already experienced such flare-ups in the past and are currently using standard COPD medications.

The treatment period will last for 108 weeks (approximately two years). Throughout the study, participants will receive regular injections of either Verekitug or placebo, while continuing their usual COPD medications. The study will monitor how well participants breathe, their quality of life, and any side effects they may experience. Blood samples will be taken to measure how the medication works in the body.

The study medication comes in the form of film-coated tablets that are taken by mouth once daily. The treatment period lasts up to 76 weeks, during which participants will receive either BI 1291583 at a dose of 2.5 mg or a matching placebo. This is part of what is called a Phase III study, which is one of the final stages of testing a new medication before it can be approved for general use.

Throughout the study, participants will be monitored for improvements in their condition, particularly focusing on how often they experience pulmonary exacerbations (sudden worsening of respiratory symptoms that require antibiotic treatment). The study will also track changes in breathing tests and how the treatment affects participants’ quality of life related to their respiratory symptoms.

The purpose of the study is to evaluate how effective and safe two different doses of CHF6001 DPI are when added to the usual maintenance therapy for COPD. This maintenance therapy typically includes a combination of inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA). The study will last for 52 weeks, during which participants will be randomly assigned to different groups. Some will receive CHF6001 DPI along with their regular treatment, while others will receive Roflumilast or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will be monitored to see how the treatments affect their COPD symptoms, particularly the frequency and severity of flare-ups, also known as exacerbations. The study will also assess changes in lung function and quality of life. By the end of the study, researchers hope to determine whether adding CHF6001 DPI to the standard COPD treatment can help reduce the number of moderate and severe exacerbations in patients with COPD and chronic bronchitis.

The purpose of the study is to see if the combination of fluticasone propionate and salbutamol sulfate can reduce severe asthma attacks when used as a rescue medication. Participants in the study will be randomly assigned to receive either the new combination treatment or the existing medication. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for a period of 35 days, during which participants will use the inhaler as needed to manage their asthma symptoms.

Throughout the study, researchers will monitor participants to see how long it takes for a severe asthma attack to occur and will also assess the overall control of asthma symptoms. The study aims to provide valuable information on whether the new combination treatment can offer better protection against severe asthma attacks compared to the existing medication. Participants’ safety will be closely monitored, and any side effects will be recorded to ensure the treatment is safe for use.

The purpose of the study is to evaluate how well CHF6001 DPI works in reducing asthma flare-ups when added to the usual asthma medications, which include medium or high doses of inhaled corticosteroids and long-acting beta2-agonists. Participants in the study will be randomly assigned to receive either CHF6001 DPI or a placebo, in addition to their regular asthma treatment, for a period of 52 weeks. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo.

Throughout the study, participants will continue their regular asthma medications and will be monitored for any changes in their asthma symptoms. The main focus will be on the number of asthma exacerbations, or flare-ups, that occur during the study period. Additional observations will include the time it takes for the first asthma exacerbation to occur and any changes in asthma control and symptoms over time. The study aims to provide valuable information on the safety and effectiveness of CHF6001 DPI as an additional treatment option for people with uncontrolled asthma.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

Participants in this study will receive either the medication BI 1291583 or a placebo, which looks like the medication but does not contain the active ingredient. The purpose of the study is to evaluate the safety of the medication by monitoring any side effects that occur during the trial. The study will also look at how the medication affects the time it takes for a lung flare-up, known as a pulmonary exacerbation, to occur and how often these flare-ups happen.

The study will last for up to 12 months, during which participants will take the medication daily. The trial is designed to be a roll-over study, meaning it includes people who have already participated in a previous study with BI 1291583. This approach helps researchers understand the long-term effects of the medication in a real-world setting. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the medication’s impact on their condition.